In January 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for cefuroxime axetil, emphasizing the need for monitoring potential adverse reactions. This underscores the importance of ongoing pharmacovigilance for established antibiotics.
In April 2023, the EMA completed a periodic safety update report (PSUR) single assessment for cefuroxime sodium (except for intracameral use), resulting in variations to the marketing authorizations to enhance safety information. This reflects the continuous efforts to ensure the safe use of cefuroxime in the EU market.
In August 2023, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of cefuroxime, highlighting its ongoing relevance in global health.
In October 2023, the CDSCO issued a directive requiring all cefuroxime manufacturers to submit updated stability data, aiming to ensure product efficacy throughout its shelf life.
In December 2023, the NPPA conducted a review of antibiotic pricing, including cefuroxime, to assess the need for potential price controls, reflecting the authority's commitment to making essential medicines affordable.
These developments highlight the dynamic regulatory environment surrounding cefuroxime, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards.
